Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study

BACKGROUND: In cardiovascular outcome trials, the sodium glucose cotransporter 2 inhibitor empagliflozin and glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide caused similar reductions in major adverse cardiac events (MACE). We compared clinical outcomes in routine clinical care. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomsen, Reimar W., Knudsen, Jakob S., Kahlert, Johnny, Baggesen, Lisbeth M., Lajer, Maria, Holmgaard, Pia H., Vedin, Ola, Ustyugova, Anastasia, Sørensen, Henrik T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483550/
https://www.ncbi.nlm.nih.gov/pubmed/34032121
http://dx.doi.org/10.1161/JAHA.120.019356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483550/
https://www.ncbi.nlm.nih.gov/pubmed/34032121
http://dx.doi.org/10.1161/JAHA.120.019356

Ejemplares similares